PUR BIOLOGICS, the regenerative therapeutics division of HippoFi, Inc. offers a portfolio of innovative biological products and proprietary technologies
ABOUT PUR
the best products and innovation combined
Focused on bringing innovative medical devices & regenerative biologic solutions, patented bioactive cellular matrix compositions, and autologous cell therapies to market for joint and spine patients.
A UNIQUE APPROACH
PRODUCTS
The Finest Products on the Market
FDA Approved Allografts & Synthetics
PUR Devices TM
PURmarrow360 TM
SAFER
Superior alternative to cell-based matrix, removing concern of disease transmission
FASTER
No centrifugation needed
OPTIMAL COLLECTION
Closed distal tip to prevent peripheral blood contamination
PUR Allografts TM
PURbonedough TM
Designed for Accelerating Cellular Ingrowth
PURFiber XP TM
Moldable Cortical Fiber
PURFlex TM
Compressible DBM Sponges
PURfuze TM
Flowable DBM Putty
PURchips TM
Cancellous Granules
PURindux TM
Cortical Fiber Strip
PUR Synthetics TM
PURbridge™
Active BioGlass Strip
PURCrystals™
BioCeramic NanoCrystals
PURcore TM
Interconnected Macroporous Matrix
PURpillars TM
Advanced Collagen Matrix Strip
TECHNOLOGY
We have solved the manufacturing challenges of ECM from cadaveric allograft tissues, that are plagued by risk of disease transmission from new viruses like Zika and SARS Cov-2 (COVID-19) and TB. Previous technologies require obtaining many human tissues from donors, usually newborn foreskin fibroblasts, in order to manufacture human ECM. Our scientists have tapped the power of Induced Pluripotent Stem Cells (IPSC) to provide a safer source of cells from a single tested donor, for ECM-producing fibroblasts under cGMP. One donor tissue sample can be effectively expanded into a single-sourced Master Cell Bank, that is safety tested and virus-free. We are currently working to complete research and development and begin commercial scale-up.
We are also using IPSC technology to make designer cell types for specialized ECM products, with more potent therapeutic and regenerative capacities. Recent research has highlighted the role of the ECM in regulating the mechanisms underlying chronic pain, and we are actively addressing the application of our ECM-technology to chronic pain and the Opioid Crisis that has resulted from over-use in recent years.
Autologous Immunotherapy Manufacturing Using New Point-of-Care Device. We have patented and are developing a new device for activating and expanding regenerative immune cells from a patient’s own bone marrow cells at the Point-of-Care: Bone Marrow Activation and Delivery Device (BMAD).
This technology can prime and activate immune cells even in older patient’s marrow that still have the capacity to differentiate into therapeutic cell types, despite the decline that occurs naturally with aging by generating meaningful numbers of MSCS, M2 Macrophages, and T-Memory Cells. This disruptive device technology solves the problems with centralized factories making immunotherapies that have driven costs to between $100,000 and $1,000,000 per treatment. These therapies will cost significantly less since they don’t require a centralized factory or complicated logistics.
Bone marrow contains stem cells of course, such as Hematopoietic and Mesenchymal, but these cells are very rare, and they cannot generally be expanded outside the body while maintaining potency. However, bone marrow aspirates contain large numbers of hematopoietic progenitor cells which our technology harnesses to provide a source of regenerative immune cells.
Though stem cells may decline with age, we have found that the committed progenitors they form ex vivo when stimulated and activated do not, and when generated ex vivo they are stimulated and activated in virtually every patient, even those above 65.
Get in touch
Our Location
9180 Irvine Center Drive
Irvine, CA 92618
Phone: 949-323-2330
Email: info@purbiologics.com
GENERAL DISCLAIMER
All statements included on this website, other than statements or characterizations of historical fact, are forward- looking statements. These forward-looking statements are based on our current expectations, estimates, projections and assumptions, and events beyond our control, all of which are subject to change. These forward-looking statements are not guarantees of future results or commitments made by us, and they are subject to risks, uncertainties and assumptions that could cause actual results to differ materially and adversely from those expressed in any forward-looking statement. The forward-looking statements on this website speak only as of the date they are made and we undertake no obligation to revise or update any forward-looking statement for any reason. This site does not constitute an offer to sell or a solicitation of an offer to buy any securities of HippoFi, Inc. (the “Company”) in any jurisdiction in which, or to any investor to whom, it is unlawful to make such offer or solicitation in such jurisdiction. The Securities and Exchange Commission and state securities regulators have not approved or disapproved of any securities of the Company, or determined if this document is truthful or complete. This website shall not be communicated, assigned, photocopied, reproduced or distributed in any way, in whole or in part, by the recipient to third parties at any time whatsoever, without the prior written consent of the Company.